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Abstract
Objective To determine whether the acute consumption of cannabis
(cannabinoids) by drivers increases the risk of a motor vehicle collision.
Design Systematic review of observational studies, with meta-analysis.
Data sources We did electronic searches in 19 databases, unrestricted
by year or language of publication. We also did manual searches of
reference lists, conducted a search for unpublished studies, and reviewed
the personal libraries of the research team.
Review methods We included observational epidemiology studies of
motor vehicle collisions with an appropriate control group, and selected
studies that measured recent cannabis use in drivers by toxicological
analysis of whole blood or self report. We excluded experimental or
simulator studies. Two independent reviewers assessed risk of bias in
each selected study, with consensus, using the Newcastle-Ottawa scale.
Risk estimates were combined using random effects models.
Results We selected nine studies in the review and meta-analysis.
Driving under the influence of cannabis was associated with a
significantly increased risk of motor vehicle collisions compared with
unimpaired driving (odds ratio 1.92 (95% confidence interval 1.35 to
2.73); P=0.0003); we noted heterogeneity among the individual study
effects (I
2=81). Collision risk estimates were higher in case-control studies
(2.79 (1.23 to 6.33); P=0.01) and studies of fatal collisions (2.10 (1.31
to 3.36); P=0.002) than in culpability studies (1.65 (1.11 to 2.46); P=0.07)
and studies of non-fatal collisions (1.74 (0.88 to 3.46); P=0.11).
Conclusions Acute cannabis consumption is associated with an
increased risk of a motor vehicle crash, especially for fatal collisions.
This information could be used as the basis for campaigns against drug
impaired driving, developing regional or national policies to control acute
drug use while driving, and raising public awareness.
Introduction
Despite being regulated in many jurisdictions, cannabis
(marijuana)isthemostwidelyusedillicitsubstanceintheworld.
Results from the 2009 Canadian Alcohol and Drug Use Survey
have indicated that 11.4% of Canadians overall and 33% of
those aged 15-24 years used cannabis at least once in the
previousyear.
1Ratesofdrivingundertheinfluenceofcannabis
have also risen in recent years; national data collected in 2004
indicatethat4%ofCanadianadultsreporteddrivingwithinone
hourofconsumingcannabis,upfrom1.9%recordedin1996-7.
2
Theseresultsarereflectedinotherjurisdictionsacrosstheworld.
A roadside survey of 537 drivers in Scotland reported that 15%
of respondents aged 17-39 years admitted to having consumed
cannabiswithin12hoursofdrivingavehicle,
3andtheEuropean
Monitoring Centre for Drugs and Drug Addiction found that
between 0.3% and 7.4% of drivers tested positive for cannabis
from roadside surveys in the United Kingdom, Denmark, the
Netherlands, Norway, the United States, and Australia.
4
Much of the early research assessing the effects of cannabis on
driving performance was done by laboratory and driving
simulator studies. The results of these studies are generally
consistent:atincreaseddoses,cannabisimpairsthepsychomotor
skills necessary for safe driving.
5-12 However, although
laboratory studies have high internal validity with regard to the
dose related effects of cannabis on performance, the
dose-responseassociationisunclearinrelationtodrivingability
andcollisionriskoutsidethelaboratory.
7 8 13 14Asaresult,these
studies do not always translate well to driving scenarios in the
real world, and generally focus on experienced cannabis users
consumingthedruginunorthodoxsurroundingsandundertaking
tasks that do not always reflect the complex nature of driving
in natural settings.
15
Observational epidemiology studies can assess driving in the
general population and are able to address many of the
limitations of laboratory studies.
16 Three types of
epidemiological studies are commonly used to investigate
cannabis use and motor vehicle collisions: cross sectional
studies, cohort studies, and case-control studies. Many cross
sectionalstudieshavereportedoncannabisincidenceininjured
or fatally injured drivers, as well as in the general driving
public.
17-23 In these studies, cannabis is consistently one of the
Correspondence to: M Asbridge mark.asbridge@dal.ca
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2012;344:e536 doi: 10.1136/bmj.e536 (Published 9 February 2012) Page 1 of 9
Research
RESEARCHmostfrequentlydetectedpsychoactivesubstances(secondafter
alcohol), and individuals who drive within two hours of using
cannabis have raised rates of collision.
24
Fewer case-control and cohort studies have looked at cannabis
consumption and collision risk, and their results have been
inconsistent.
5 25-27Morethanhalfofthesestudieshavesuggested
that cannabis consumption is associated with an increased risk
of traffic collision,
21 23 28 and the remaining studies have found
no association or a decreased risk of collision.
29-33 Researchers
have also used a variant of case-control designs, often known
as culpability studies.
34 Culpability studies include drivers
involvedincollisions,separatedintothosewhowereresponsible
for the collision and those who were not. The premise of these
studies is that, if cannabis use increases collision risk, the drug
should more likely be detected in drivers judged to be
responsible for their collision. However, culpability analyses
have also produced mixed results.
35-39
Therefore, a lack of consensus exists on whether the risk of
motor vehicle collisions is elevated or lowered when drivers
haverecentlyconsumedcannabis.Furthermore,veryfewrobust
studies on this subject are generalisable to situations in the real
world.Anuptodatesystematicreviewisnecessarytointegrate
the existing evidence on the role of cannabis use on collision
risk, not only from a public policy and programme perspective,
but also in view of the current gaps in scope and quality of
literature and methodology.
We did a systematic review of the observational epidemiology
literaturetoascertainwhethertheacuteconsumptionofcannabis
or cannabinoids by drivers increases the risk of a motor vehicle
collision, and to explore the impact of potential biases due to
outcome measurement and confounding on the observed effect
sizes.
Methods
Weusedasystematicreviewapproachsimilartothatadvocated
by the Cochrane Collaboration,
8 appropriately modified for the
epidemiological nature of our review objective and available
data. We included a comprehensive search, transparent study
selection and data extraction, risk of bias assessment, and
synthesisofsufficientlysimilardata.Weselectedobservational
studies with a control or comparison group, including cohort
(historical prospective), case-control, and culpability designs.
We excluded experimental laboratory or simulator studies. We
included studies if they assessed acute or recent cannabis use
by the toxicological analysis of whole blood or via self report,
with participants drawn from hospital studies, roadside studies,
studiesofcollisions(includingfatalcollision)drawnfrompolice
records, and self report studies.
We included studies that assessed motor vehicle collisions,
defined by the World Health Organization as “a collision or
incidentthatmayormaynotleadtoinjury,occurringonapublic
road and involving at least one moving vehicle.”
40 Motor
vehiclesincludedcars,vans,sportutilityvehicles,lightorheavy
trucks, buses, motorcycles or scooters, all terrain vehicles, and
snowmobiles. Collision outcomes included single or multiple
vehicles, which might have led to injuries or death, and could
be measured via administrative data or self report. We did
separateassessmentsoftheimpactofcannabisconsumptionon
fatal or non-fatal outcomes and on case-control or culpability
studies.
Literature search and selection
The search strategy included several data sources and was not
restricted by language of publication or by year. We did
electronic searches in the following databases, with the help of
anexperiencedlibraryscientist:theCochraneLibrary(including
theCochraneCentralRegisterofControlledTrials(CENTRAL),
Cochrane Database of Systematic Reviews (CDSR), Database
ofAbstractsofReviewsofEffects(DARE),HealthTechnology
Assessment (HTA) Database, NHS Economic Evaluation
Database (EED)), Medline, Embase, PsycInfo, Cumulative
Index to Nursing and Allied Health Literature, SocIndex,
Sociological Abstracts, Web of Science, Academic Search
Premier, ProQuest Library, Alcohol Studies Database, the
Alcohol and Alcohol Problems Database, LegalTrac,
Transportation Research Information Service (TRIS) database
Online, and OSHLINE.
Searches were conducted between 13 August and 2 September
2010. We used the following search terms, and adapted these
for each database if appropriate:
• ((“Accidents, Traffic”[MeSH]) OR (“Motor
Vehicles”[MeSH])) OR (accident* OR crash* OR
collision* OR collide*) AND
• (car OR automobile* OR vehicle* OR traffic* OR road
OR “off-road”) AND
• ((“Cannabis”[MeSH] OR “Cannabinoids”[MeSH]) OR
“Marijuana Smoking”[MeSH]) OR
(“Tetrahydrocannabinol”[MeSH])OR(hempORcannabis
OR Marihuana OR marijuana OR pot OR hashish OR
Ganja OR thc OR Tetrahydrocannabinol)).
In addition to the electronic search, we browsed reference lists
of included studies and related reviews identified in the
electronic search, and reviewed the personal libraries of the
research team. We included published reports investigating the
association between cannabis use and motor vehicle collision.
Tworeviewers(MAandJLC)independentlyscreenedthesearch
resultsandidentifiedstudiesthatwerepotentiallyrelevant.They
reviewed studies in three stages, based on each paper’s title,
abstract, and full text. The reviewers reached consensus at each
stage of the screening process.
Data collection
For selected studies, two reviewers (MA and JLC) extracted
data separately using pretested data extraction forms. They
discussed any discrepancies in data extraction and sought the
assessment of a third reviewer (JAH) for resolution. Extracted
information included relevant study details (authors, year,
geographical area, study design, sample size), population
characteristics(meanage,malesex,setting),exposure(method
and timing), bivariate and multivariate associations between
exposure and outcome, and the incidence of outcomes from
motor vehicle collisions for each study population and for the
unexposedgroup(toallowcomparisonsacrosspopulationsand
outcome measures).
Quality assessment for individual studies
Two reviewers (MA and JLC) assessed the quality of each
selected study using the Newcastle-Ottawa scale.
41 This scale
awards a maximum of nine stars to each study: four stars for
the adequate selection of cases and controls, two stars for
comparability of cases and controls on the basis of the design
and analysis, and three stars for the adequate ascertainment of
the exposure in both the case and control groups. We defined
studies of high quality as those that scored the maximum nine
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RESEARCHstarsontheNewcastle-Ottawascale;studiesofmediumquality
scored seven or eight stars. One discrepancy in quality
assessment was discussed and resolved by the two reviewers.
Synthesis of results
Study estimates of the effect of cannabis on collision risk are
often confounded by the failure to separate out the effects of
alcohol and other psychoactive substances. Therefore, our
analyses focused on tetrahydrocannabinol, the main
psychoactive component of cannabis. We searched for any
positivetestforactivemetabolitesoftetrahydrocannabinol,and
assessed the presence of tetrahydrocannabinol alone, in the
absenceofalcoholorotherdrugs.Ourprimaryanalysisfocused
on measures that best captured recent use: consumption
measured by the presence of active tetrahydrocannabinol
metabolites or 11-hydroxy-delta-9-tetrahydrocannabinol in
blood.
Odds ratios were extracted from each study, or were calculated
by the reviewers (MA and JLC) if the odds ratio of interest was
not explicitly stated. In the event of missing information, study
authors were contacted by email. In addition to our primary
analysis, we used subgroup analyses to explore the effects of
study design, quality, and outcome on estimates of risk.
Meta-analyses used random effects modelling and
Mantel-Haenszel estimates in Review Manager 5.1 (Cochrane
Collaboration,Oxford,UK).Weratedtheoverallqualityofour
evidence by considering the internal validity, generalisability,
heterogeneity, and precision of included studies, following
recommendations by the Grading of Recommendations
Assessment, Development and Evaluation Working Group.
Results
Study selection
Our literature search found 2975 studies; we selected 222 for
abstract review, and brought forward 23 for full text review.
Weidentifiedanother16studiesfromreferencesearching.One
paper from the reference search was selected for inclusion,
together with nine from the full text search (fig 1⇓).
We excluded studies after full text review that analysed the
presence of inactive metabolites of tetrahydrocannabinol, or
those with urine and blood test results that could not be
separated. Although three of the included studies did test for
the presence of cannabinoids in urine, we included data only if
the presence of the active metabolite was also confirmed by a
blood sample.
23 39 42 After data extraction, we excluded another
studybecauseitcontainedduplicateddatafromapreviouspaper
(fig 1).
Characteristics of included studies
The meta-analysis included observational studies of motor
vehicle drivers who had been treated for serious injuries
sustained in a crash or had been involved in a fatal crash
(table⇓).
23 39 42 43 44 45 46 47 48 All studies tested for
tetrahydrocannabinolbyanalysingbloodsamplesorusingdirect
self reports of cannabis use in the three hours before the crash,
and all analyses included the active form of
tetrahydrocannabinol. Studies were a mixture of case-control
and culpability designs, were undertaken in different countries,
andusedvariousdatasourcessuchasmedicalrecords,roadside
testing stations, administrative data (that is, the Fatal Accident
Reporting System), and coroners’ reports. Rates of cannabis
use for cases ranged from 2% to 15%, with rates for controls
ranging from less than 1% to 7%.
Risk of bias assessment
Four studies were deemed to be of high quality and five of
medium quality; no studies were rated as low quality. Of the
medium quality studies, one reported large differences in
response rates for cases and controls, but lacked objective
confirmation of self reported marijuana use.
44 Another study
showed a potential bias in participant selection because it used
data only from drivers aged 20-49 years.
43 The remaining three
studies were not clear about which factors were controlled for
in their analyses of results.
42 43 44
Across studies, the main bias related to exposure measurement
was the concurrent use of alcohol or other drugs in addition to
cannabis.Althoughdatawereavailableforalcohol,insufficient
informationwasavailabletoaccountfortheeffectofotherillicit
drugs.Sincethisbiaswouldoverestimatetheeffectofcannabis
on collision risk, we calculated odds ratios using “cannabis
only” cases and controls—that is, only those motorists whose
system contained cannabis without any other drugs or alcohol
present.
Sevenofthenineincludedstudiesfoundthattheriskofamotor
vehiclecollisionincreasedwhendrivershadconsumedcannabis
within a few hours before the crash,
39 42 43 44 45 46 47 with two
studies concluding that the risk of a collision while under the
influence of cannabis was less than the risk for unimpaired
drivers.
23 48 The positive association between cannabis use and
motor vehicle collision risk ranged from 1.36 (95% confidence
interval 0.59 to 3.15)
42 to 7.16 (2.77 to 18.52)
44 (fig 2⇓). Most
studies used 1 ng/ml of cannabis or any amount greater than
zero as the cutoff for a positive test result,
23 39 43 45 46 47 48 with
one study using a 2 ng/ml cutoff
42 and another using only self
report.
44
Primary and secondary analyses
Our primary analysis looked at the risk of a motor vehicle
collision while under the influence of cannabis and included all
nine studies (relating to 49 411 participants). The pooled risk
of a motor vehicle collision while driving under the influence
of cannabis was almost twice the risk while driving unimpaired
(odds ratio 1.92 (95% confidence interval 1.35 to 2.73);
P=0.0003); we noted heterogeneity among the individual study
effects (I
2=81%).
We also assessed culpability and non-culpability studies
separately and explored differences between motor vehicle
collisions resulting in deaths and non-fatal injuries.
Meta-analyses on subgroups of studies explored the potential
effect of specific features related to study design and potential
biases: case-control studies versus culpability studies, fatal
collisions versus non-fatal collisions, and high quality studies
versus medium quality studies (fig 3⇓).
High quality studies had a pooled odds ratio that was higher
than that for medium quality studies, although both results
showed a significant association at the 0.05 level. Furthermore,
case-control studies (2.79 (1.23 to 6.33); P=0.01) estimated the
effect of cannabis use on crash risk to be higher than that
estimated by culpability studies (1.65 (1.11 to 2.46); P=0.07).
Studies of fatal collisions (2.10 (1.31 to 3.36); P=0.002) had a
pooled odds ratio that was statistically significant, but studies
ofnon-fatalcollisions(1.74(0.88to3.46);P=0.11)didnotshow
significant results.
Inallstudiesassessingcannabisuseinconjunctionwithalcohol,
theestimatedoddsratioforcannabisandalcoholcombinedwas
higher than for cannabis use alone, suggesting the presence of
a synergistic effect.
21 23 35 37
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RESEARCHOverall quality of evidence
The overall quality of the evidence on the association between
cannabis use and motor vehicle collisions was moderate. Most
studies in our meta-analysis consistently showed an increased
effect of cannabis use on the risk of motor vehicle collisions.
All studies were graded seven points or above on the nine point
Newcastle-Ottawa scale for quality. The studies were
heterogeneous (as shown in our primary analysis), and we used
random effects models for the meta-analyses. Confidence
intervals for most of the subgroup analyses were narrow.
Overall, we regarded our results to be generalisable to cannabis
related crashes resulting in serious injuries or death, in which
alcohol and other drugs are not confounding factors.
Publication bias
Figure 4⇓ shows a funnel plot examining possible publication
bias. These results should be interpreted with caution, because
our meta-analysis included only nine studies, and current
guidelinesdonotrecommendtestingforfunnelplotasymmetry
in analyses of fewer than 10 studies.
49 Nevertheless, we did not
see evidence of important small study bias or publication bias.
Discussion
After a systematic review of the literature, this meta-analysis
of studies examining acute cannabis consumption and motor
vehicle collisions, with adequate control groups, found a near
doubling of risk of a driver being involved in a motor vehicle
collision resulting in serious injury or death. The increased risk
was most evident for high quality studies, case-control studies,
and studies of fatal collisions. The impact of acute cannabis
consumption on the risk of minor crashes remains unclear. To
our knowledge, this meta-analysis is the first to examine the
association between acute cannabis use and the risk of motor
vehicle collisions in real life settings. This review is important
to enhance our understanding of the effects of cannabis
consumption on collision risk, and provides a more definitive
statement on the direction that efforts in public policy and
intervention should take in addressing road safety.
These results converge with those from experimental studies
(laboratory, simulator, and forensic) suggesting that cannabis
impairsperformanceofthecognitiveandmotortasksnecessary
for safe driving, increasing the risk of collision.
10 11 The results
also accord with recent data for collisions that point to the
increasing presence of drugs other than alcohol (especially
cannabis and depressants of the central nervous system) in
injured and fatally injured drivers.
50 51 Surveys of young drivers
have also shown that rates of driving under the influence of
cannabis have surpassed rates of drinking and driving in some
jurisdictions.
24 52 Nevertheless, alcohol remains the substance
most often present in crashes, and the observed association
betweencannabisconsumptionandcrashriskislessrobustthan
that for alcohol.
53 54 For example, a blood alcohol concentration
of0.8g/100mL(17.36mmol/l),whichisthecriminalthreshold
for impairment in many jurisdictions, is associated with an
increased relative risk of a crash of 2.69, with a substantially
higher risk for drivers aged 35 years and younger.
54 55
Studies included in the meta-analysis showed considerable
heterogeneityoftheeffectofcannabisuse.
49Differencesinrisk
estimates between culpability and case-control studies might
have been partly due to the nature of the non-culpable group
that acts as a control group in culpability studies. By definition,
people in this group are not true controls, because they have
been involved in a motor vehicle collision but have been found
not at fault for the crash. Therefore, baseline crash risk in
non-culpabledriversisbiasedupwards,withsmallereffectsizes
than would be found in a crash free control, and might mitigate
the effect of tetrahydrocannabinol on crash risk in culpability
studies. Differences in the nature of the control groups between
study designs could account for the more conservative effect
estimatedfromtheculpabilitystudies,aswellasfromthestudies
of medium quality.
We observed that cannabis had an increased influence on the
risk of motor vehicle collision for studies of fatally injured
drivers, which might be explained by the differences in
tetrahydrocannabinol concentrations. Although we did not
examine dose effects on the risk and severity of collisions,
studies of fatally injured drivers found higher amounts of
tetrahydrocannabinol in the blood (either by heavier
consumption of cannabis or owing to the shorter time period
between consumption and measurement) than those observed
in studies of non-fatal injuries.
50 56 57 For fatally injured drivers,
tetrahydrocannabinol is measured at a time equivalent to death,
as opposed to non-fatal crashes in which the compound is
assessed many hours after the crash. Furthermore, drivers in
non-fatal crashes are more likely to refuse drug testing,
increasing the measurement bias.
Simulator studies have also found a substantial dose-response
effect, in which raised concentrations of tetrahydrocannabinol
were associated with increased crash risk. Only three of the
reviewedstudiesincludedcalculationsofoddsratiosatdiffering
tetrahydrocannabinolconcentrations;inallthreestudies,raised
amountsofthesubstanceincreasedtheriskofcrash.
23 39 45Since
only one of the included studies assessed infrequent or habitual
use of cannabis by drivers, we were unable to distinguish
between tetrahydrocannabinol amounts in occasional and
habitual cannabis users.
44
Limitations
Legal thresholds for driver impairment due to cannabis
consumptionareinconsistent;thejudgmentofimpairmentvaries
indifferentregions,fromobservedimpairmentviasobrietytest
results only to measured tetrahydrocannabinol amounts in the
blood or serum of 7-10 ng/ml.
56 Furthermore, such thresholds
arelessmeaningfulinviewofevidenceindicatingthatcannabis
impairment can be at its peak despite low measurements of
tetrahydrocannabinol in the blood.
58 Furthermore, the presence
of cannabis at the time of a collision is calculated differently
across studies (on the basis of serum, whole blood, or self
report), and could include subjective measures of acute
consumptionorrecentuse.Severaljurisdictionshaveattempted
to legislate cannabis use by drivers by using a zero tolerance
policy
50 our review lends weight to their assumption that recent
cannabis use increases motor vehicle collision risk. However,
the studies in our review did not have enough data on
tetrahydrocannabinol concentration to examine dose-response
effects. Therefore, our data cannot assess legislation based on
legal thresholds of cannabis impairment.
We found considerable heterogeneity across the studies in our
review (I
2=81%). We used a random effects model after
postulatingapriorithatourpopulationswouldbeheterogeneous,
because of varying data sources and the differing methods used
to measure tetrahydrocannabinol concentrations. Although we
defined high quality studies as those that scored full marks on
the Newcastle-Ottawa scale, many of these high and medium
quality studies probably did not control for all possible
confounders. Although we restricted positive cannabis results
to drivers that showed the presence of tetrahydrocannabinol in
theabsenceofotherdrugsoralcohol,otherpotentiallyimportant
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RESEARCHconfounders were probably not controlled for. These hidden
confounders, as well as the differing study designs used, might
have affected the results of the individual studies and hence the
estimates of the pooled odds ratios.
Using our inclusion criteria, we selected only studies of serious
injuries and deaths resulting from motor vehicle collisions.
Cannabis might also be a risk factor for minor collisions,
although the association between cannabis consumption and
collisionswassignificantforfatalmotorvehiclecollisions,and
not significant for non-fatal crashes. Tetrahydrocannabinol
concentrations might also be important, with minor collisions
more likely than fatal collisions to involve drivers with lower
concentrations of cannabis. Future reviews could assess minor
collisions with control groups drawn from the general driving
population.
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Table 1| Characteristics of the nine studies included in the meta-analysis
Quality† THC test procedure Data setting Controls Cases No of
participants
in sample*
Outcome Study
design
Year Authors
Medium Testing of whole blood
by coroners
Fatal Accident
Reporting System
database
Non-culpable
drivers
Culpable drivers 32 543 Deaths Culpability 2007 Bedard et al
Medium Self report of acute
THC use in 3 hours
before crash
Roadside testing,
medical and police
records
Random sample of
drivers from
roadside
Drivers in
crashes
1139 Deaths Case-control 2005 Blows et al
High Testing of whole blood
by coroners
Medical and police
records
Non-culpable
drivers
Culpable drivers 1590 Deaths Culpability 2004 Drummer et
al
High GCMS on whole blood Medical and police
records
Non-culpable
drivers
Culpable drivers 6765 Deaths Culpability 2005 Laumon et al
Medium RIA followed by
GCMS on whole blood
Emergency
departments
Non-culpable
drivers
Culpable drivers 1975 Injuries Culpability 2000 Longo et al
Medium Self report or
screening of serum,
confirmed by GCMS
Roadside testing,
medical and police
records
Random sample of
drivers from
roadside
Injured drivers 3679 Injuries Case-control 2005 Mathijssen et
al
Medium GCMS on whole blood Emergency
departments
Other attendees of
emergency
department
Drivers
attending the
emergency
department
631 Injuries Case-control 2003 Mura et al
High RIA followed by
GCMS on whole blood
Medical and police
records, Fatal
Accident Reporting
System database
Non-culpable
drivers
Culpable drivers 799 Deaths Culpability 1992 Terhune
High Screening and testing
of blood plasma
Emergency
departments
Non-culpable
drivers
Culpable drivers 290 Injuries Culpability 1982 Terhune
THC=tetrahydrocannabinol; GCMS=gas chromatography and mass spectrometry; RIA=radioimmunoassay.
*Numbers represent the samples used in the present review and meta-analysis (THC only, no alcohol, or other drugs present), and do not represent the total
numbers of participants in the original studies.
†Measurement based on the Newcastle-Ottawa scale.
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RESEARCHFigures
Fig 1 Study selection for systematic review
Fig 2 Meta-analysis of observational studies investigating the association between acute cannabis consumption and motor
vehicle crashes
Fig 3 Pooled odds ratio (95% CI) of motor vehicle collision risk with tetrahydracannabinol for subgroups of studies
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RESEARCHFig 4 Funnel plot examining possible publication bias in studies investigating the association between acute cannabis
consumption and risk of motor vehicle crashes. The horizontal axis measures the association (odds ratio) observed in
individual studies, plotted against the standard error. The broken vertical line indicates our overall pooled estimate from
meta-analysis (odds ratio 1.92)
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